Karyopharm Therapeutics
KPTI
118 hedge funds and large institutions have $103M invested in Karyopharm Therapeutics in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 35 closing their positions.
331% more call options, than puts
Call options by funds: $785K | Put options by funds: $182K
38% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 29
0.27% less ownership
Funds ownership: 4.77% → 4.5% (-0.27%)
14% less funds holding
Funds holding: 137 → 118 (-19)
29% less capital invested
Capital invested by funds: $145M → $103M (-$42.2M)
54% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.51M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.8M |
| 3 |
JP Morgan Chase
New York
|
+$1.57M |
| 4 |
Morgan Stanley
New York
|
+$931K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$850K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.2M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.3M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.65M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$1.47M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.26M |
KPTI Hedge Fund Activity: Q3 2023 in Review
118 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2023, worth a combined $103M — down 29% from $145M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of KPTI and 16 opened new positions — a net loss of 19 holders — while 29 trimmed existing stakes and 40 added.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $2.51M. The largest seller was Opaleye Management, exiting entirely with an estimated $3.2M sold.
- 118 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2023, down from 137 in Q2 2023.
- Funds reported $103M of Karyopharm Therapeutics stock for Q3 2023, down 29% quarter-over-quarter.
- 16 funds opened new Karyopharm Therapeutics positions in Q3 2023 and 35 closed out, a net change of -19 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2023 was Jacobs Levy Equity Management, an estimated $2.51M added.
- The largest Karyopharm Therapeutics seller in Q3 2023 was Opaleye Management, an estimated $3.2M sold.
Based on aggregated 13F filings for Q3 2023.